Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Miron

Showing results (41-50 of 42) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 42 results.
Molecular Cancer Research : MCR|December 10, 2013
NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growthShannon T Bailey, Penelope L Miron, Yoon J Choi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinomaT Ciuleanu, I Bazin, D Lungulescu, et al.
Pageof 5

Showing results (41-50 of 42) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 42 results.
Molecular Cancer Research : MCR|December 10, 2013
NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growthShannon T Bailey, Penelope L Miron, Yoon J Choi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinomaT Ciuleanu, I Bazin, D Lungulescu, et al.
Pageof 5